ResearchAndMarkets.com's offering.
The global market for G-Protein Coupled Receptors (GPCRs) estimated at US$2.9 Billion in the year 2022, is projected to reach a revised size of US$4.7 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2022-2030. Cell Lines, one of the segments analyzed in the report, is projected to record a 6% CAGR and reach US$1.8 Billion by the end of the analysis period.
Taking into account the ongoing post pandemic recovery, growth in the Detection Kits segment is readjusted to a revised 6.7% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 8.9% CAGR
The G-Protein Coupled Receptors (GPCRs) market in the U.S. is estimated at US$1.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$416.9 Million by the year 2030 trailing a CAGR of 8.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 6.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.
Select Competitors (Total 52 Featured) -
Addex Pharmaceuticals Ltd.
Impact of Covid-19 and a Looming Global Recession Influencer Market Insights
World Market Trajectories
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Important Role of GPCRs in Drug Discovery
Popular Types of GPCRs of Therapeutic Interest
Physiological Roles Performed by GPCRs
Geographic Market Analysis
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Therapeutic Potential of GPCRs Gains Wide Recognition
Allosteric Modulators and Implication of Allostery in Drug Discovery
GPCRs Registered as Targets for Approved Drugs with EMBL-CHEMBL, IUPHAR, and The DrugBank
GPCRs Registered as Targets for Approved Drugs with EMBL-CHEMBL
GPCRs Registered as Targets for Approved Drugs with International Union of Basic and Clinical Pharmacology (IUPHAR)
GPCRs Registered as Targets for Approved Drugs with The DrugBank
FDA Approved GPCR Targeting Drugs (Excl. Diagnostic Agents) for the Period 2015-2019 Developments in Structural Biology and Receptor Pharmacology Offer Novel Opportunities to GPCR Drug Discovery In Silico Approaches Underway for GPCR Drug Screening Microfluidic Cell Technology Holds Potential
Pipeline GPCR Drug Candidates Widen Prospects Select GPCR Small Molecule Drugs in Active Clinical Development GPCR Ligands (Agonist) in Phase III Clinical Development GPCR Ligands (Antagonist) in Phase III Clinical Development New Indications to Aid Growth
CRISPR Holds Potential to Speed Up GPCR-based Drug Discovery Select FDA Approved Drugs and Antibodies against Various Cancer Types Anti GPCRs Drugs and Antibodies under Clinical Trials
Rising Incidence of Cancer to Drive Drives Opportunities Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 GPCRs Evolve as Important targets for developing novel therapeutics for Neurodegerative Disorders
Number of Individuals Suffering from Alzheimer's in the US: 2020 and 2025
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
GPCRs: An Important Target for Cardiovascular Drugs
4. GLOBAL MARKET PERSPECTIVE
For more information about this report visit https://www.researchandmarkets.com/r/nebkmj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets